loading
Idexx Laboratories, Inc. stock is currently priced at $496.95, with a 24-hour trading volume of 883.85K. It has seen a -0.56% decreased in the last 24 hours and a +0.85% rose in the past month. The chart indicates a potential bearish trend, as the stock is below the $498.9 pivot point. If it approaches the $495.9 support level, significant changes may occur.
Previous Close:
$499.77
Open:
$500.17
24h Volume:
883.85K
Market Cap:
$41.04B
Revenue:
$3.72B
Net Income/Loss:
$866.57M
P/E Ratio:
50.71
EPS:
9.8
Net Cash Flow:
$796.79M
1W Performance:
-3.79%
1M Performance:
+0.85%
6M Performance:
+6.68%
1Y Performance:
+6.92%
1D Range:
Value
$491.16
$504.72
52W Range:
Value
$372.50
$583.39

Idexx Laboratories, Inc. Stock (IDXX) Company Profile

Name
Name
Idexx Laboratories, Inc.
Name
Phone
207-556-0300
Name
Address
One IDEXX Drive, Westbrook, ME
Name
Employee
8,000
Name
Twitter
@idexx
Name
Next Earnings Date
2024-05-29
Name
Latest SEC Filings
Name
IDXX's Discussions on Twitter

Idexx Laboratories, Inc. Stock (IDXX) Upgrades & Downgrades

Date Action Analyst Rating Change
Jan-30-24 Downgrade Piper Sandler Overweight → Neutral
Dec-07-23 Initiated Exane BNP Paribas Outperform
Dec-04-23 Upgrade Cleveland Research Neutral → Buy
Aug-02-23 Downgrade Atlantic Equities Overweight → Neutral
Jul-25-22 Downgrade Stifel Buy → Hold
Jul-21-22 Upgrade Goldman Neutral → Buy
Jul-12-22 Initiated Piper Sandler Overweight
May-05-22 Downgrade BofA Securities Buy → Neutral
Feb-08-22 Initiated Atlantic Equities Overweight
Nov-18-21 Initiated Morgan Stanley Overweight
Aug-05-21 Resumed Credit Suisse Outperform
Jul-12-21 Downgrade Guggenheim Buy → Neutral
Feb-17-21 Initiated Barclays Overweight
Sep-09-19 Initiated Goldman Neutral
May-23-19 Initiated Guggenheim Buy
Nov-02-18 Reiterated BofA/Merrill Buy
May-07-18 Reiterated Stifel Buy
Jan-16-18 Initiated Piper Jaffray Overweight
Aug-23-17 Upgrade BofA/Merrill Neutral → Buy
Jul-28-17 Upgrade CL King Neutral → Buy
Feb-03-17 Downgrade Feltl & Co. Hold → Sell
Sep-29-16 Resumed BofA/Merrill Neutral
Aug-16-16 Reiterated Stifel Buy
Aug-03-16 Upgrade Northcoast Sell → Neutral
Jul-20-16 Reiterated Canaccord Genuity Buy
Apr-19-16 Reiterated Canaccord Genuity Buy
Apr-01-16 Initiated CL King Neutral
Mar-21-16 Reiterated Stifel Buy
Feb-04-16 Initiated Credit Suisse Outperform
Oct-29-15 Reiterated Stifel Buy
Aug-28-15 Downgrade Raymond James Outperform → Mkt Perform
Aug-13-15 Reiterated Stifel Buy
Jul-23-15 Reiterated Canaccord Genuity Buy
View All

Idexx Laboratories, Inc. Stock (IDXX) Financials Data

Idexx Laboratories, Inc. (IDXX) Revenue 2024

IDXX reported a revenue (TTM) of $3.72 billion for the quarter ending March 31, 2024, a +8.57% rise year-over-year.
loading

Idexx Laboratories, Inc. (IDXX) Net Income 2024

IDXX net income (TTM) was $866.57 million for the quarter ending March 31, 2024, a +23.94% increase year-over-year.
loading

Idexx Laboratories, Inc. (IDXX) Cash Flow 2024

IDXX recorded a free cash flow (TTM) of $796.79 million for the quarter ending March 31, 2024, a +74.86% increase year-over-year.
loading

Idexx Laboratories, Inc. (IDXX) Earnings per Share 2024

IDXX earnings per share (TTM) was $10.33 for the quarter ending March 31, 2024, a +24.31% growth year-over-year.
loading

Idexx Laboratories, Inc. Stock (IDXX) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Claflin Bruce L.
Director
May 17 '24
Sale
540.80
200
108,160
161
Kingsley Lawrence D
Director
May 06 '24
Option Exercise
0.00
339
0
8,883
SZOSTAK M ANNE
Director
May 06 '24
Option Exercise
0.00
257
0
257
Vandebroek Sophie V.
Director
May 06 '24
Option Exercise
0.00
257
0
1,473
COLLINS Asha
Director
May 06 '24
Option Exercise
0.00
257
0
779
ESSIG STUART
Director
May 06 '24
Option Exercise
0.00
257
0
1,974
AYERS JONATHAN W
Director
May 06 '24
Option Exercise
0.00
257
0
265,651
Britt Irene Chang
Director
May 06 '24
Option Exercise
0.00
208
0
208
POLEWACZYK JAMES F
Executive Vice President
Mar 06 '24
Option Exercise
422.45
8,104
3,423,547
18,815
POLEWACZYK JAMES F
Executive Vice President
Mar 06 '24
Sale
558.44
8,104
4,525,596
10,711
IDEXX Laboratories, Inc., together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. It operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments. The company provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. It also offers diagnostic and health-monitoring products for livestock, poultry, and dairy markets; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers that are used in the human point-of-care medical diagnostics market. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was founded in 1983 and is headquartered in Westbrook, Maine.
diagnostics_research IQV
$219.09
price down icon 1.51%
diagnostics_research A
$130.41
price down icon 0.77%
diagnostics_research MTD
$1,404.09
price up icon 1.48%
$324.82
price up icon 0.59%
diagnostics_research WAT
$308.90
price up icon 0.42%
Cap:     |  Volume (24h):